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Modulation of Suppressor Mechanisms in Allergic Contact Dermatitis: 5. 
Evidence That Inhibition of Suppressor T Lymphocytes by 
Corynebacterium parvum Is Mediated by Interferon 
JURGEN KNOP, M.D., PH.D., RAINER RlECHMANN, M :D ., CHRISTINE N EUMANN, M .D., AND 
EGON MACHER, M.D. 
Departm.ent of Experimental Derm.atoiogie, University of 1I1iinster, M iinster, F.R.C. 
Using a contact hypersensitivity model in BALB/c 
!Dice we have previously been able to show that Cory-
nebacteriumparvum or C. parvum serum (C.p.s .) of mice 
treated 24 hI' before with C. parvum inhibited the sup-
pressor T-lymphocyte (Ts-cell) response induced by epi-
cutaneous antigen overload with 2,4-dinitrofluoroben-
zene (DNFB) or by i.v. injection of 2,4-dinitrobenzene 
s ulfonic acid (DNBS03) without inhibition of the T effec-
tor cell response (TDH-cell). In the present investigation 
~e further analyzed the factor responsible for Ts-cell 
inhibition. Treatment of the C.p.s. with sheep-antimouse 
interferon (IFN) globulin neutralized its Ts-cell inhibi-
tory effect. Intravenous (i.v.) injection of a crude mouse 
fibroblast IFN (340 U per mouse) 2 hr after i.v. applica-
t ion of a dose ofDNBS03 inducing tolerance had a similar 
Ts-cell inhibitory effect as observed with C.p.s. Injection 
of an electrophoretically pure ex- and f3-IFN preparation 
(1000 U per mouse) increased contact sensitivity in mice 
sensitized with an antigen overload and inhibited the 
induction of Ts-cells by DNBS03 i.v. This result is highly 
s uggestive that the Ts-cell inhibitory factor in serum of 
C. parum-treated mice is IFN and it shows that Ts-cells 
as compared to TOIl-cells are susceptible to the inhibitory 
effect of highly purified IFN. This finding suggests that 
IFN may be an important immunoregulatory factor of 
delayed hypersensitivity not only in contact allergy but 
also in bacterial and viral defense. 
We recently demonstrated that in contact allergy of BALBI 
c mice to 2,4-dinitroflu orobenzene (DNFB) pretreatment of the 
a nimals with COIynebacterium parvum resulted in an increased 
immune r esponse of otherwise partially tolerant animals by 
e picutaneous antigen overload [1]. Fwther analysis of this 
mechanism revealed that C_ parmun injected 1 or 2 weeks 
b efore sensit ization with an antigen overload suppressed the 
s uppressor cell responses in th ese animals [I). Induction of 
s uppressor T-lymphocytes (Ts-cell) by intravenous injection of 
2,4-dinitrobenzene sulfonic acid (DNBSO:) was also inhibited 
by prior C. parvum t reatment as shown by transfer experiments 
[2). Serum of mice injected 6 or 24 hI' before with C. parvum 
intraperitoneally (i.p.) showed a similar inhibitory effect on 1'8-
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lymphocytes in th e antigen overload experiment as well as in a 
model using DNBS03 as inducer of l' -cells . This serum as well 
as C. parvum itself had no suppressive effect on TDwcelis [3). 
We have now analyzed t he T s-lymphocyte inhibitory activity 
in this serum and t here is strong evidence that this activity is 
due to interferon (IFN) . 
MATERIALS AND METHODS 
Mice 
BALB/c mice were purchased from the Zentraiinstitut fur Versuchs-
tierzucht, Hannover, FRG, kept under conventional condit ions, and 
used at t he age of 10 to 12 weeks. 
R eagents 
C. parvum strain CN 6134 lot CA 761 (Wetlcome Reseru'ch Labora-
tory, Beckenham, GB), was heat inactivated. DNFB and DNBS03NA 
were obtained from Sigma Chemical Co., Munchen, FRG. C. parvwn 
serum (C.p.s.) was obtained from BALB/ c mice injected 24 h1" before 
wi th 2.8 mg C. parvum per mouse i.p. [3). A sheep antimouse IFN 
globulin and a normal sheep gamma globulin was kindly provided by 
Dr. I. Gresser (for details of specificity and strength see [4]). A highly 
purified mouse fi broblast IFN preparation was obtained from Dr. E. 
De Maeyer, Institut Clu-ie, Orsay. In terferon was prepared in mouse C-
243 cells by induction with Newcastle disease virus. It was purified by 
sequential cl)J'omatography on sephru-ose-bound poly-U and anti-IFN 
globulin as previously described [5). E lectrophoretic analysis on poly-
acryla mide gel, followed by staining with Coomassie BriUiant Blue, 
revealed only the 3 IFN bands, corresponding to moleculru' weigh ts of 
35, 28, and 22K , and no contaminating bands. The 35 a nd 28K species 
correspond to mouse ,B-IFN and the 22K to mouse a-IFN [6). The 
pUl'ified IFN was stabilized with 0.5% BALB/ c serum. A mouse fibro-
blast IFN preparation was obtained from the National Institutes of 
Health , Bethesda, Mru'yland (NIH Ref. Stand. G-0020-004-51l). A 
human fibroblast IFN prepru'ation was also obta ined from the NIH 
(NIH R ef. Stand. G-023-902-527) . 
Interferon Assay 
A cytopathic effect inhibition assay with mouse L cel.ls (clone 929) 
and vesicular stomatitis vi.rus (Indiana strain) was used [7). 
Sensitization. and E licitation of DNFB Contact Sensitivity 
This has been described previously [1,2]. In short, mice were sensi-
tized with DNFB (15 /-il. 0.5%) by 2 daily paintings on the clipped 
abdomen. T he ear was painted on t.he dorsum with 0.3% DNFB on day 
5 and ear thickness measured using an engineer's micrometer 24 and 48 
hr later. Suppression by ant igen overload [1,8] was induced by 2 daily 
paintings with an increased dose of DNFB (50 ILl , 0.5%). Tolerance was 
induced by intravenous (i.v.) inj ection of 15 mg DNBS03 per mouse. 
Preparation and Transfer of Spleen Cells 
This has been described in detail [2]. Spleen ceUs from sensit ized or 
to lerant donor mice were prepru'ed in Dulbecco's minimum essential 
medium (Dulbecco's MEM), supplemented with 10% fetal calf serum 
and injected i.v. into the recipient mouse (1 x 108 spleen cetls per 
mouse). Two hours after injec tion of the cetls the mice were either 
cha llenged or sensit ized as described above [1,9]. 
Statistical Analysis 
All dat.a al'e expressed as mean ± standard deviation and were 
analyzed by one-way analysis of vru'iants fo llowed by Scheffe's test for 
leasl significant difference. 
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RESULTS 
Spleen cells (s.c. ) fro m donor a nimals made tolerant to 
DNBS03 were a ble to transfer suppression of contact sensitivity 
to naive recipients (Fig Ib) which h ad been sensitized and 
challenged similarly to t he positive control (Fig la). As shown 
previously, transferable suppression by spleen cells requires 
living T-Iymphocytes in th e s.c. population [2,9]. These cells 
are referred to as T wcells. Transfer of s .c. from donors injected 
i.v. with 1 ml of C.p.s. 2 hr after being m ade tolerant by i.v. 
injection of DNBSOa did not result in a suppression of contact 
sensitiv ity in th e recipient animals, i.e., no functionally active 
Ts-cells were presen t in this s.c. population (Fig I e). The T s-
cell inhibitory activity of C.p.s. could be completely abrogated 
by pretrea ting the serum for 1 hr at room temperature with 
an timouse IFN globulin at a dilu tion of 1: 500, and significant 
neutralization was also observed at a dilution of 1: 50,000 (Fig 
If, g). We have s hown previously that C. paruum-induced an-
tiviral activity could be completely neutralized by this antise-
rum [7]. An amount of anti-IFN-globulin sufficien t to neu t ralize 
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FIG 1. Donor mice were made tolerant by i.v. injection of 15 mg 
DNBSO" pel' mouse. After 6 days s.c. from the donors were transferred 
to naive recipients (1 X 108 s.c. per mouse Lv.) which were sensitized 
twice with 0.5% DNFB and challenged on the right ear 5 days later. 
Ear swelling was measured after 24 hr. a, Positive control, sensitized 
and challenged as described. b- h, Donor made tolerant and treated as 
described using 1.0 ml normal serum, 1.0 ml C.p.s., anti-lFN, or sheep 
gamma globulin. i, Negative control (ear challenge in nonsensitized 
animals). 
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FIG 2. Effect of a crude mouse fibroblast lFN preparation (Ref. 
Sland. IFN ) on the induction of Twcells. For experimental design, see 
legend for Fig 1. a, Positive controL b-g, Donor made tolerant and 
treat.ed as described. Group a, c, and d significantly increased over b, t, 
and g. Pooled results of 2-3 experiments. 
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FIG 3. Effect of lFN on contact sensitivity in animals sensitized with 
an optimal amount of DNFB (15 J.L I) and by epicutaneous antigen 
overload (50 J.LI). BALB/c mice were sensitized with 15 J.LI (optimal) or 
50 J.L1 0.5% DNFB by painting the shaved abdominal skin on 2 following 
days. IFN or buffer (0.5 ml/mouse) was injected i.v. once 2 hI' after the 
fU'st sensitization. At day 5, ear challenge was performed by painting 
the right ear with 20 J.LI 0.3% DNFB; 24 hI' late r ear thickness was 
measured, and ear swelling was calculated as difference of ear thickness 
of the unchallenged (left) and challenged (right) ear. The resul ts of 1-
3 experimen ts are presented as mean ear swell ing ± S.D. All data were 
analyzed by one-way analysis of variants followed by Scheffe's test for 
least significant difference. Statistical analysis: group a not different 
from b; group c increased over a and b; group d increased over a and 
b; group e not different from a and b ; group t not different li'om g, h , 
fl, and j; group h (nonsensitized animals, ear challenged) less than all 
other groups. 
40 U of IFN per ml [7] could a lso inhibit th e effect of C.p.s. on 
T s-ceUs. The normal sh eep ganuna globulin had no neut ra lizing 
effect on t he T s inhibitory activity of C.p.s. (Fig Ih) . Normal 
BALB/c serum h ad no T s-ceU inhibitory activity (Fig lc,d). 
The amount of IFN found in 24-w' serum samples using a 
cytopathic effect inhibition assay (see under Materials a nd 
Methods) was 5-10 U pel' mi. 
In Fig 2 the resul ts of experiments are shown in which we 
injected the R ef. Stand . IFN i.v. 2 W· after the donor was m ade 
tolerant (Fig 2d). This r esulted in an abrogation of th e T s-cell 
response since no suppression could b e transferred to the recip-
ient a nimals (Fig 2d ) by the s.c. from the tolerant IFN-treated 
donors. The T s-cell inhibitory effect was similar to that ob-
served with C.p.s. (Fig 2c ). Thirty-foUl' units of IFN were s till, 
although slightly, inhibitory for T s (Fig 2e ) , while 3.4 U had no 
effect (Fig 2f) , nor did 300 U of IFN treated with a nti-IFN 
globulin (1 :500) (Fig 2g). 
In the following series of experiments we injected highly 
purified mouse a- and ,8-IFN intravenously . In Fig 3 the results 
of experiments are shown in which the effect of highly pUl'ified 
IFN on contact sensitivity in animals sensit ized with an a ntigen 
overload (50 III DNFB) was studied. Injection of 1000 (Fig 3c) 
01' 100 U (Fig 3d ) IFN 2 hr after the first sensitization with a n 
a ntigen overload resulted in an increased ear swelling in com-
parison to that found in un treated or buffer-treated controls. 
Ear swelling was not diminished in animals treated with IFN 2 
W· after optimal sensitization (Fig 3f-j). In the experiments 
shown in Fig 4, T s-cells were again induced by i.v. injection of 
15 mg DNBS03 per mouse [5]. Intravenous injection of 1000 U 
IFN 2 hI' after i.v. injection ofDNBSO:] inhibited the generation 
of T s cells (Fig 4d), i.e., no suppression could be transferred 
with the s.c. of' IFN-trea ted a nimals to the recipients as com-
pared with th e untreated (Fig 4b) 0)' buffer-treated (Fig 4c) 
control. One hunched uni ts of IFN (Fig 4e ) was mar ginally 
effective, 10 U (Fig 4f) had no e ffect. Pretreatment of the donor 
animals with human fibroblast IFN (500 U per animal) had no 
inhibitory effect on the T s-ceLls (resul ts not s hown). 
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FIG 4. Effect of highly purilied IFN on the Ts-cell response in the 
spleen cell donor treated with DNBS03 i.v. Mice treated with DNBSO:) 
i.v. (15 mg/mouse) to induce Ts-ceLls were injected i.v. with IFN or 
buffer 2 hr la ter. After 6 days, s.c. suspensions were prepared and 
t ransferred by i.v. injection to na ive recipients (1 x 108 cell/ mouse). 
The recipients were sensitized with 151110.5% DNFB and challenged as 
described (see legend for Fig 1) . The results are expressed as mean ± 
S.D. from 2-3 experiments. a, Optimally sensitized animals. Groups b-
f, Ear swelling in recipients receiving s.c. from DNBSO:)-treated donors. 
b , No further t reatment of donors. c, Donors inj ected i.v. with 0.5 ml 
buffer. d-(, Donors injected i.v. with 0.5 ml IFN (1000, 100, 10 U). g, 
Unsensitized, ear challenged control. Statistical analysis: group bless 
than a; group c less than a; group c not different from b; group d not 
different fi'om Ct.; group cl increased over band c; groups e and f not 
different !i'OIn band c. Group b < Ct.; C < u.; c = b; d = a; d> band c; 
e,{ = b,c. 
DISCUSSION 
Taken together, these results ru'e highly suggestive that the 
active molecule in the C.p.s. which inhibits the T s-cell response 
is IFN. Previous result& [1-3] have shown that C.p.s. and C. 
paruum itself had no or only very slight effects on the generation 
and function ofTDwcells. Present data would indicate that very 
low amounts of IFN found in the serum of C. paruum-treated 
mice may efficiently suppress the action of certain lymphocyte 
s ubpopulations in vivo which are functionally chru'acterized by 
suppression of antigen-specific TDwcells. It should be men-
tioned that the antimouse IFN gamma globulin may possibly 
also be directed against other mouse components. However, we 
believe that following findings-(l) IFN is produced by injec-
tion of C. paruum, (2) the Ts-inhibitory activity is neutralized 
by anti-IFN, (3) that a crude and a highly purified IFN have a 
s imilru' effect as C.p.s.-provide sufficient evidence to suggest 
that IFN is the responsible factor. Most of the biologic effects 
of crude IFN preparations which in many experiments could be 
neutralized by the anti-IFN gamma globulin used in our study 
could be reproduced with the highly purified IFN as discussed 
by Gresser et al [10]. 
Using an antivu'al assay, low amounts of IFN were demon-
strable in the C.p.s. The antiviral activity of C. paruum-induced 
IFN [7] and the Ts-inhibitory activity of the C.p.s. are relatively 
stable to pH 2 as shown previously [3], indicating type 1 IFN 
(a- and ,B-IFN) as active molecules. 
The C.p.s. containing 5-10 U of IFN according to om assay 
inhibited Ts more efficiently than the two IFN preparations 
(~100-1O00 U). This discrepancy may be explained by some 
inactivation of the purified prepru'ations during the experimen-
tal procedure (highly purified IFN is very labile); or the serum 
may also contain other IFN types with preferential antiproli-
ferative or other cell regulatory effects potentiating the Ts-
inhibitory activity of (X- and ,B-IFN. Recently Evans and John-
son [11] reported that C. parUlun induces IFN-n/ -,B and IFN-y 
in mouse spleen cell cultures. In this context it would be 
interesting to compare the efficiencies of the various IFN types 
to inhibit the Ts-ceU response. 
Interferons have been shown to affect immune reactions in 
vitro and in vivo (for review see [12]) . Theu'llnmunoregulatory 
functions have evoked considerable interest [13]. In many ex-
perinlental systems, IFN has been shown to suppress the im-
mune response in vitro and in vivo [14] , whereby high amounts 
of IFN were required. However, recent publications show that 
delayed hypersensitivity as well as the primary antibody re-
sponse to T-dependent antigens could be enhanced in vivo 
when IFN was administered shortly after immunization [9,15]. 
It should be mentioned that C.p,s., most likely the IFN activity 
in it, and highly purified IFN convert a sUboptinlal response to 
DNFB into a fully expressed reaction which involves elilnina-
tion of T s-cells. The mechanisms of the IFN interference with 
the manifestation of the T s-cell response is uncleru'. Since in 
this study the IFN effect on T s-cells has been demonstrated 
mostly by transfer experiments, it is important to exclude 
effects of cell homing by the prepru'ation used. Al'guments 
against this possibility are: (1) C.p.s. [3] and IFN ulcreased 
contact sensitivity in the antigen overload model (no transfer 
of cells). (2) It is unlikely that cell homing will be affected 6 
days after injection of C.p.s. or IFN. (3) In a recent publication 
Gresser et al [16] demonstrated that IFN, even at a concentra-
tion of 104 units, did not alter cell homing. The target cell of the 
IFN effect may then be the T s-cell (inhibition of proliferation 
and /or function) or cells involved in the regulation of the Ts-
cell response such as contrasuppressor cells [17]. This question 
awaits fmther analysis. 
Our findings suggest that IFN may be an important umnuno-
regulatory factor in delayed hypersensitivity. Inhibition of the 
T s-cell response of delayed-type hypersensitivity by C. parvUln, 
mediated by IFN induced by a bacterial product, may be a 
control mechanism of the immune response to vi.ral and bacte-
rial infections. This mechanism could also be of some relevance 
for the ilnmune stimulatory function of adjuvants of the bac-
terial type. So fru' nothing is known of the effect of IFN on T s 
cells controlling the antibody response. 
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Optimization of Bioavailability of Topical Steroids: Thermodynamic 
Control 
ROGER WOODFORD, PH.D. ' AND BRIAN ' W . BARRY, PH.D., D.Se. 
School of Pharmacy, Portsmouth Polytechnic, Portsmouth, and Postgraduate School of Studies in Phar/nacy, University of Bradford, 
Bradford, Englan.d 
In theory, under strictly defined ideal conditions, the 
bioavailability of a drug from a topical formulation 
should depend only on the thermodynamic activity of 
the medicament in the base. We tested this fundamental 
postulate using a steroid as the test drug, formulated in 
a series of ' solutions and gels at 90% saturation, i.e., 
ideally at constant thermodynamic activity. The in vivo 
assessment method was the occluded vas()constrictor 
test in humans. For most systems, this simple measure 
of thermodynamic activity correlated with drug bioa-
vailability as assessed by the blanching response. Where 
there were differences, we have rationalized them in 
terms of penetration enhancement, irritancy, dehydra-
tion of the stratum corneum, or steroid binding in the 
base, although such factors have not been explicitly 
demonstrated. 
When modern formulators develop dermatologic prepara-
tions for optimum bioavailability, they employ two main meth-
ods of approach, either singly or combined. The first sch eme 
formulates the vehicle in such a way that the drug h as the 
maximum tendency to leave the base and to partition into the 
skin, with no intention that t he vehicle components should 
affect the physicochemical properties of the stratum corneum. 
Thus the vehicle design promotes drug release by simply optim-
izing the thermodynamic activity of the medicament. The al-
ternative method . of approach is to incorporate into the for-
mulation materials, known as penetration enhancers, i.e., chem-
icals which themselves permeate the skin, dynamically a nd 
reversibly decreasing the r esistance of the stratum corneum to 
the penetration of the drug. This paper discusses the thermo-
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dynamic approach and a second investigation reports on the 
effect of penetration enh ancers. 
The aim of this study therefore is to investigate the vasocon-
strictor activities and, by inference, the clinical anti- inflamma-
tory efficacies a nd bioava ilabilities of a range of optimized 
formulations of the topical steroid, mecWorosone dibutyrate. 
The bioassay employed is t h e occluded vasoconstrictor test [1-
4]. 
MATERIALS AND METHODS 
Six solutions (fu'st series) and 6 gels (second series) or the composi-
tion listed in Table I were used as received from Unilabo, France. In 
each of these systems, the solvent compositions had been adjusted so 
that the steroid was at 90% saturation, i.e., ideally at the same ther-
modynamic activity. This is a simplification as the chemical potential 
of a real system will depend on concentration in a different way for 
different nonideal systems. However, the assumption that all the for-
mulations at 90% saturation are at the same thermodynamic activ ity 
provides us with a starting point to examine any deviations. Betnovate 
cream (betamethasone as valerate, 0.1%) was used as a standard prep-
aration to control the vasoconstrictor test. 
Subjects 
Ten volunteers were selected; none had received topical cortico-
steroid application for at least two months prior to the study. 
Method 
Two trials were performed, one for the solu tions and one for the gels. 
Five microliters of each of the test solutions (or 5 .mg of each gel) and 
5 mg Betnovate cream were applied at sites on the washed flexor 
surface of each forearm. The application sites consisted of 7 x 7 mm 
areas punched-out from Blenderm tape, to which formu lations were 
applied using a random design. The sites were occluded with type S12 
/.1m Melinex film for 6 hr. Tapes and films were removed and the areas 
were washed with soap and water at body temperature and were dried. 
Readings were taken in a double-blind manner after 10 min and after 
1, 2, 3, 6, 18, 26, 42, 66, 74, and 90 hr to provide data points for skin 
blanching at 6, 7,8,9, 12, 24, 32. 48, 72, 80, and 96 hr after application. 
Assessment was made according to a 0-4 scale with half-point ratings 
for intermediate readings: 0 = normal skin, 1 = sligh t vasoconstriction 
